知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

12 records (took 0.032 seconds)

    METHODS AND COMPOSITIONS FOR TREATING CANCER USING PD-1 AXIS ANTAGONISTS AND HPK1 ANTAGONISTS
    7.
    发明申请
    METHODS AND COMPOSITIONS FOR TREATING CANCER USING PD-1 AXIS ANTAGONISTS AND HPK1 ANTAGONISTS 审中-公开

    公开(公告)号：US20180280505A1

    公开(公告)日：2018-10-04

    申请号：US15885040

    申请日：2018-01-31

    Applicant: Genentech, Inc.

    Inventor： Sairy Hernandez ,  Ira Mellman ,  Jing Qing ,  Deepak Sampath

    IPC: A61K39/395 ,  C07K16/28

    Abstract: Compositions and methods for enhancing an immune response and treating cancer are provided. Compositions comprise PD-1 axis antagonists and HPK1 antagonists. PD-1 axis antagonists include PD-1 antagonists, PD-L1 antagonists, and PD-L2 antagonists. PD-1 axis antagonists can inhibit the binding of PD-L1 and/or PD-L2 to PD-1. HPK1 antagonists include compounds that inhibit the serine/threonine kinase activity of HPK1. Methods for enhancing an immune response or treating cancer comprise administering a PD-1 axis antagonist and a HPK1 antagonist, sequentially or simultaneously, to a subject in need thereof.

    METHODS AND COMPOSITIONS FOR TREATING CANCER USING PD-1 AXIS ANTAGONISTS AND HPK1 ANTAGONISTS
    9.
    发明申请
    METHODS AND COMPOSITIONS FOR TREATING CANCER USING PD-1 AXIS ANTAGONISTS AND HPK1 ANTAGONISTS 审中-公开
    使用PD-1轴的ANTAGONISTS和HPK1拮抗剂治疗癌症的方法和组合

    公开(公告)号：US20160158360A1

    公开(公告)日：2016-06-09

    申请号：US14959221

    申请日：2015-12-04

    Applicant: Genentech, Inc.

    Inventor： Sairy Hernandez ,  Ira Mellman ,  Jing Qing ,  Deepak Sampath

    IPC: A61K39/395 ,  A61K45/06

    CPC classification number: A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/76

    Abstract: Compositions and methods for enhancing an immune response and treating cancer are provided. Compositions comprise PD-1 axis antagonists and HPK1 antagonists. PD-1 axis antagonists include PD-1 antagonists, PD-L1 antagonists, and PD-L2 antagonists. PD-1 axis antagonists can inhibit the binding of PD-L1 and/or PD-L2 to PD-1. HPK1 antagonists include compounds that inhibit the serine/threonine kinase activity of HPK1. Methods for enhancing an immune response or treating cancer comprise administering a PD-1 axis antagonist and a HPK1 antagonist, sequentially or simultaneously, to a subject in need thereof.

    Abstract translation: 提供了增强免疫应答和治疗癌症的组合物和方法。 组合物包含PD-1轴拮抗剂和HPK1拮抗剂。 PD-1拮抗剂包括PD-1拮抗剂，PD-L1拮抗剂和PD-L2拮抗剂。 PD-1轴拮抗剂可以抑制PD-L1和/或PD-L2与PD-1的结合。 HPK1拮抗剂包括抑制HPK1的丝氨酸/苏氨酸激酶活性的化合物。 增强免疫应答或治疗癌症的方法包括将PD-1轴拮抗剂和HPK1拮抗剂依次或同时施用于有需要的受试者。

Patent Agency Ranking